{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:10:06Z","timestamp":1790518206563,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Fam Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polypharmacy is defined as the prescription of at least 5 different medicines for therapeutic or prophylactic effect and is a serious issue among elderly patients, who are frequently affected by multi-morbidity. Deprescribing is one of the proposed approaches to reduce the number of administered drugs, by eliminating those that are inappropriately prescribed. The aim of this systematic review is to provide an updated and systematic assessment of the benefit-risk profile of deprescribing of anti-hypertensive drugs, which are among the most commonly used drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEDLINE, EMBASE and The Cochrane Library were searched for studies assessing the efficacy and safety of anti-hypertensive drugs deprescribing in the period between January, 12,016 and December, 312,019. The quality of randomized clinical trials (RCTs) was assessed using the GRADE approach for the evaluation of the main outcomes. The risk of bias assessment was carried out using the Cochrane risk-of-bias tool.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, two RCTs were identified. Despite summarized evidence was in favor of anti-hypertensive deprescribing, the overall risk of bias was rated as high for each RCT included. According to the GRADE approach, the overall quality of the RCTs included was moderate regarding the following outcomes: systolic blood pressure\u2009&lt;\u2009150\u2009mmHg after 12\u2009weeks of follow-up, quality of life, frailty and cardiovascular risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This updated systematic review of the efficacy and safety of anti-hypertensive treatment deprescribing found two recently published RCTs, in addition to the previous guideline of the National Institute for Health and Care Excellence (NICE). Evidence points towards non-inferiority of anti-hypertensive deprescribing as compared to treatment continuation, despite the quality of published studies is not high. High quality experimental studies are urgently needed to further assess the effect of deprescribing for this drug class in specific categories of patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12875-021-01557-y","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T02:35:53Z","timestamp":1634697353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Salvatore","family":"Crisafulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Luxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Coppini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Zinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziano","family":"Onder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"1557_CR1","unstructured":"National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management [Internet]. 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ng56\/resources\/multimorbidity-clinical-assessment-and-management-pdf-1837516654789"},{"key":"1557_CR2","doi-asserted-by":"crossref","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230","DOI":"10.1186\/s12877-017-0621-2"},{"key":"1557_CR3","unstructured":"Italian Medicines Agency. National Report on Medicines use in Italy [Internet]. 2019. Available from: https:\/\/www.aifa.gov.it\/documents\/20142\/1205984\/rapporto-osmed-2019.pdf\/f41e53a4-710a-7f75-4257-404647d0fe1e"},{"key":"1557_CR4","doi-asserted-by":"publisher","unstructured":"Shah H, Shah NJ. Drug Interactions. Introd to Basics Pharmacol Toxicol [Internet]. Singapore: Springer Singapore; 2019. p. 197\u2013204. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-981-32-9779-1_12","DOI":"10.1007\/978-981-32-9779-1_12"},{"key":"1557_CR5","doi-asserted-by":"crossref","unstructured":"Italiano D, Spina E, De Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10(11):1457\u201389.","DOI":"10.1517\/17425255.2014.956081"},{"key":"1557_CR6","doi-asserted-by":"crossref","unstructured":"Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74(1):15\u201327.","DOI":"10.1007\/s00228-017-2357-5"},{"key":"1557_CR7","unstructured":"Sindhu MS, Kannan B. Investigating the factors affecting drug-drug interactions. Int. J Pharma Bio Sci. 2013;4(4):P467\u2013P476"},{"key":"1557_CR8","doi-asserted-by":"crossref","unstructured":"Reis AMM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics. 2011;66(1):9\u201315","DOI":"10.1590\/S1807-59322011000100003"},{"key":"1557_CR9","doi-asserted-by":"crossref","unstructured":"Moura C, Acurcio F, Belo N. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266\u201372","DOI":"10.18433\/J35C7Z"},{"key":"1557_CR10","doi-asserted-by":"crossref","unstructured":"Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583\u2013623","DOI":"10.1111\/bcp.12975"},{"key":"1557_CR11","unstructured":"Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. Am Fam Physician. 2019;100(1):32\u201338"},{"key":"1557_CR12","doi-asserted-by":"crossref","unstructured":"Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, et al. Withdrawal of antihypertensive drugs in older people. Cochrane Database Syst Rev. 2020;6(6):CD012572","DOI":"10.1002\/14651858.CD012572.pub2"},{"key":"1557_CR13","doi-asserted-by":"crossref","unstructured":"Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of Deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35(4):303\u201319","DOI":"10.1007\/s40266-018-0536-4"},{"key":"1557_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2174\/138920011796504473","volume":"12","author":"G Trifiro","year":"2011","unstructured":"Trifiro G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12:611\u201320 Available from: http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1389-2002&volume=12&issue=7&spage=611.","journal-title":"Curr Drug Metab"},{"key":"1557_CR15","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;6(7):e1000097","DOI":"10.1371\/journal.pmed.1000097"},{"key":"1557_CR16","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928","DOI":"10.1136\/bmj.d5928"},{"key":"1557_CR17","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"1557_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1161\/01.CIR.51.6.1107","volume":"51","author":"ED Freis","year":"1975","unstructured":"Freis ED. Return of elevated blood pressure after withdrawal of antihypertensive drugs. Circulation. 1975;51:1107\u201313 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1093758.","journal-title":"Circulation"},{"key":"1557_CR19","doi-asserted-by":"crossref","unstructured":"Greenberg G. Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. Medical Research Council working party on mild hypertension. Br Med J (Clin Res Ed). 1986;293:988\u201392.","DOI":"10.1136\/bmj.293.6553.988"},{"key":"1557_CR20","doi-asserted-by":"crossref","unstructured":"Maland LJ, Lutz LJ, Castle CH. Effects of withdrawing diuretic therapy on blood pressure in mild hypertension. Hypertens (Dallas, Tex 1979);5:539\u201344.","DOI":"10.1161\/01.HYP.5.4.539"},{"key":"1557_CR21","doi-asserted-by":"crossref","unstructured":"Sheppard JP, Burt J, Lown M, Temple E, Lowe R, Fraser R, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA J Am Med Assoc. 2020;323(20):2039\u201351","DOI":"10.1001\/jama.2020.4871"},{"key":"1557_CR22","doi-asserted-by":"crossref","unstructured":"Luymes CH, Poortvliet RKE, van Geloven N, de Waal MWM, Drewes YM, Blom JW, et al. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial. BMC Med. 2018;16(1):5","DOI":"10.1186\/s12916-017-0988-0"},{"key":"1557_CR23","doi-asserted-by":"crossref","unstructured":"Greenberg G. Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. Br Med J (Clin Res Ed). 1986;293(6553):988\u201392","DOI":"10.1136\/bmj.293.6553.988"},{"key":"1557_CR24","doi-asserted-by":"crossref","unstructured":"Touyz RM. Hypertension guidelines: effect of blood pressure targets. Can J Cardiol. 2019;35(5):564\u20139","DOI":"10.1016\/j.cjca.2019.03.014"},{"key":"1557_CR25","doi-asserted-by":"crossref","unstructured":"Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Intern Med. 2015;175(6):989\u201395","DOI":"10.1001\/jamainternmed.2014.8012"},{"key":"1557_CR26","doi-asserted-by":"crossref","unstructured":"Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30(2):173\u20138","DOI":"10.1111\/j.1365-2710.2005.00629.x"},{"key":"1557_CR27","doi-asserted-by":"crossref","unstructured":"Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45(3):203\u201333","DOI":"10.1080\/15563650701226192"},{"key":"1557_CR28","unstructured":"Rosas-Carrasco \u00d3, Garc\u00eda-Pe\u00f1a C, S\u00e1nchez-Garc\u00eda S, Vargas-Alarc\u00f3n G, Guti\u00e9rrez-Robledo LM, Ju\u00e1rez-Cedillo T. The relationship between potential drug-drug interactions and mortality rate of elderly hospitalized patients. Rev Investig Clin. 2011;63(6):564\u201373"},{"key":"1557_CR29","doi-asserted-by":"crossref","unstructured":"L\u00e9tinier L, Cossin S, Mansiaux Y, Arnaud M, Salvo F, Bezin J, et al. Risk of drug-drug interactions in out-hospital drug dispensings in France: results from the DRUG-drug interaction prevalence study. Front Pharmacol. 2019;10:265","DOI":"10.3389\/fphar.2019.00265"},{"key":"1557_CR30","doi-asserted-by":"crossref","unstructured":"Formica D, Sultana J, Cutroneo PM, Lucchesi S, Angelica R, Crisafulli S, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681\u201395","DOI":"10.1080\/14740338.2018.1491547"},{"key":"1557_CR31","unstructured":"Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane Collab. 2011."}],"container-title":["BMC Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-021-01557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-021-01557-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-021-01557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T02:36:59Z","timestamp":1634697419000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-021-01557-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1557"],"URL":"https:\/\/doi.org\/10.1186\/s12875-021-01557-y","relation":{},"ISSN":["1471-2296"],"issn-type":[{"value":"1471-2296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In the last 5\u2009years, GT has served on a number of advisory boards organized by pharmaceutical companies on topics that are not related to the topic of this systematic review. GT is the principal investigator of observational studies funded by several pharmaceutical companies (e.g. Amgen, AstraZeneca and Daiichi Sankyo) for the University of Messina\/Academic Spin-Off INSPIRE. The other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}